(Press-News.org) University of Maryland School of Medicine Dean, Mark T. Gladwin, MD, announced today the appointment of distinguished parasitologist and immunologist Stefan Kappe, PhD, to be the new Director of the school’s Center for Vaccine Development and Global Health (CVD). He will also serve as the Myron M. Levine, MD, DTPH Professor of Vaccinology in the Department of Pediatrics.
Dr. Kappe is a Professor and the Associate Vice Chair of Basic Science Research in the Department of Pediatrics at the University of Washington in Seattle. He is also a senior principal investigator at the Center for Global Infectious Disease Research at Seattle Children’s Research Institute where he recently also served as an Associate Director. Dr. Kappe is internationally known for his transformational work in genetic engineering of parasites, which has led to a novel malaria vaccine type that demonstrated the potential to provide a high level of protection against malaria infection in preclinical models and a clinical study. He is also recognized for his landmark research on the early phases of malaria parasite infection in the liver.
He plans to begin his new position early next year; James Campbell, MD, MS, Professor of Pediatrics at the UM School of Medicine, will continue to serve as Interim Director of CVD until that time. He took over in July from Miriam Laufer, MD, who had been serving as Interim Director since April 2024.
Dr. Kappe’s laboratory focuses on understanding the complex pathobiology of malaria parasites and immune responses to infection, with the goal of designing transformational interventions that are more effective than current malaria treatments and vaccines. Along with his research team, he has pioneered functional genomics studies and reverse genetics studies of malaria parasites, laying the foundations for their in-depth biological investigation. They have used this knowledge to develop genetically engineered vaccine strains, which have become leading vaccine candidates and are currently tested in early-stage clinical trials in the US, Germany and Burkina Faso.
Dr. Kappe has received more than $34 million in funding from the National Institutes of Health (NIH) and other funding sources such as the Gates Foundation since 2003, and he continues to have strong NIH funding support through P01, R01 and U01 grants. His research is focused on developing genetically engineered live-attenuated pathogens to optimize safety and potency against Plasmodium falciparum malaria infection as well the identification of targets of protective immunity for subunit vaccine development. His team also investigates the molecular drivers of Plasmodium vivax, the parasite most responsible for recurrent malarial infections, and its persistence in the human liver to develop potential new therapeutics.
With a significant h-index of 65, Dr. Kappe’s research has been cited more than 6,300 times. He has authored or contributed to more than 280 publications, including 24 reviews on the basic science aspects of host-parasite interaction of malaria, pathophysiological and clinical aspects of Plasmodium infection, malaria vaccine development, and humanized mouse models of Plasmodium infection.
“Dr. Kappe has made it his life’s mission to develop a highly effective vaccine against malaria, which due to the limitations of the current immunizations, remains one of the greatest global health problems with hundreds of millions of infections and more than half a million deaths each year in the developing world,” said Dean Gladwin who is also the Vice President for Medical Affairs, at the University of Maryland, Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and Dean. “His deep expertise in malaria biology and immunology, combined with his mentorship in basic and translational science, will strengthen CVD’s global leadership in combating malaria, tropical diseases, and emerging pandemics driven by climate change. I want to express my deepest appreciation to Dr. Campbell and Dr. Laufer for serving so adeptly at the helm of CVD until a permanent director could be appointed.”
As part of his role as the Myron M. Levine, MD, DTPH Professor of Vaccinology, Dr. Kappe will serve as Vice Chair of Translational Research in the Department of Pediatrics at the UM School of Medicine. He will develop and implement a translational research road map for the Department of Pediatrics and will launch strategies for promoting and growing the department's research portfolio, which will include research collaborations and mentoring. He plans to launch investigative studies focusing on early-life pediatric immunity versus adult life immunity as an important topic for future vaccine development.
“I am thrilled to welcome Dr. Kappe to our Department and expect he will play an integral role in helping to grow our research program and to further our capabilities in interdisciplinary bench discovery for novel pediatric vaccines,” said Steven Czinn, MD, Chair of the Department of Pediatrics at the UM School of Medicine.
CVD was the first center in the world to develop controlled human malaria infection studies, providing proof of principle that live attenuated malaria vaccines protect against infection. Faculty have been conducting genome-wide studies of antimalarial drug resistance and have tested monoclonal antibodies for treating malaria. Since CVD was founded more than 50 years ago, CVD faculty, consisting of basic science researchers and physician-scientist clinicians, have worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. They were the first in the country to test the mRNA vaccine against COVID-19 and have created and tested vaccines against numerous infectious diseases including cholera, typhoid fever, paratyphoid fever, non-typhoidal Salmonella disease, shigellosis (bacillary dysentery), E. coli diarrhea, nosocomial pathogens, tularemia, influenza, coronaviruses, malaria, and other infectious diseases.
“I am very honored and humbled to become the new Director of this world class research center to help facilitate the use of genetic advances for urgently needed innovation that will hopefully lead to a new generation of life saving immunizations,” said Dr. Kappe. “I am thrilled to be working alongside such leaders in this field and am also eager to recruit and mentor young faculty on their journey to establishing successful, sustainable and collaborative research programs.”
Dr. Kappe is a national leader in the vaccine field for his innovative work to genetically engineer live attenuated Plasmodium parasites to develop safer and more effective malaria vaccines. Last year, his lab collaborated with biotechnology company Sanaria to use genetic engineering to develop a novel malaria vaccine, PfSPZ-LARC2. The vaccine demonstrated the potential to provide high-levels of protection against malaria infection, which makes it a promising candidate for a more potent immunization. His work has been cited in prestigious journals such as EMBO Molecular Medicine, Nature Microbiology and Science. The vaccine candidate developed from his work recently had initial clinical trials published in the New England Journal of Medicine.
Dr. Kappe is or has been a member of the American Society of Tropical Medicine and Hygiene, American Society of Microbiology, American Society for Cell Biology and the American Society for Biochemistry and Molecular Biology. For his excellence and contributions towards a highly protective malaria vaccine, he has received the Sornchai Looareesuwan Medal, given in recognition of his accomplishments. For his work in malaria research, he has also received the William Trager Award in Basic Parasitology and the Bailey K. Ashford medal awarded at the American Society of Tropical Medicine Meeting in 2016.
He received his PhD in molecular biology and parasitology from the University of Notre Dame and undergraduate degree in biology from the Rheinische-Friedrich Wilhelms University in Germany.
About the University of Maryland School of Medicine
The University of Maryland School of Medicine, established in 1807 as the first public medical school in the U.S., continues today as one of the fastest growing, top-tier biomedical research enterprises in the world. The School has nearly $500 million total research funding, 46 departments, centers, and institutes, more than 2,200 student trainees and over 3,000 faculty members, including notable members of the National Academy of Medicine. As the largest public medical school in the DC/MD/VA region, faculty-physicians are working to help patients manage chronic diseases like obesity, cancer, heart disease and addiction, while also working on cutting-edge research to address the most critical generational health challenges. In 2024, the School ranked #12 among public medical schools and #27 among all medical schools for R&D expenditures by the National Science Foundation. With a $1.3 billion total operating budget, the School partners with the University of Maryland Medical Center to serve nearly 2 million patients annually. The School's global reach extends around the world with research and treatment facilities in 33 countries. In Maryland, the School of Medicine is spearheading new initiatives in AI and health computing and partnering with the University of Maryland BioPark to develop new medical technologies and bioengineering ventures. For more information, visit medschool.umaryland.edu.
About the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine
For over 40 years, researchers in the Center for Vaccine Development and Global Health (CVD) have worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. CVD is an academic enterprise engaged in the full range of infectious disease intervention from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments. CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal Salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, coronaviruses, malaria, and other infectious diseases. CVD’s research covers the broader goal of improving global health by conducting innovative, leading research in Baltimore and around the world. Our researchers are developing new and improved ways to diagnose, prevent, treat, control, and eliminate diseases of global impact, including COVID-19. In addition, CVD’s work focuses on the ever-growing challenge of antimicrobial resistance.
END
Internationally recognized malaria researcher Stefan Kappe, Ph.D., appointed new director of the UM School of Medicine's Center for Vaccine Development and Global Health
2025-09-08
ELSE PRESS RELEASES FROM THIS DATE:
Lung cancer genetics study launches open-source data platform to research community
2025-09-08
23andMe Research Institute, Troper Wojcicki Philanthropies (TWP), and Lifebit today announced the official launch of an open-source data platform for the Lung Cancer Genetics Study. Launched in 2024, the Lung Cancer Genetics Study aims to enroll 10,000 individuals diagnosed with lung cancer by 2027. The study already includes more than 1,200 participants and is one of the most diverse cohorts ever assembled for lung cancer genetics research.
This marks a new phase in the study — with researchers now able to request access to de-identified data from consenting study participants and begin conducting analyses. This unique research program ...
Pre-conception radiation exposure from CT scans increases risk for miscarriage and birth defects
2025-09-08
Embargoed for release until 5:00 p.m. ET on Monday 8 September 2025
Follow @Annalsofim on X, Facebook, Instagram, Bluesky, and Linkedin
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their ...
Boston University appoints Kenneth Lutchen to top research job
2025-09-08
Boston University has appointed pioneering biomedical engineer and experienced higher education leader Kenneth Lutchen as its new vice president and associate provost for research. He will lead BU’s $500 million research enterprise, which spurs new knowledge and impactful advances. In the past year alone, BU researchers have launched a global AI-powered infectious diseases monitoring tool, engineered devices that could improve cancer treatment, and landed a telescope on the moon.
Lutchen has held a variety of teaching and leadership positions since ...
For video-on-demand platforms, release strategy matters: streaming episodes gradually boosts consumers’ searches, subscription rates
2025-09-08
The market for video-on-demand platforms has grown rapidly in the last decade, with nearly 90% of U.S. households subscribing to a service, and most subscribers having four or more platforms. In this context, and as more than a third of U.S. subscribers cancel their subscriptions within short periods, retaining subscribers and maximizing engagement have become crucial to the industry.
In a new study, researchers examined how the release strategy of shows—gradually or all at once—influences users’ engagement and subscription rates at a video-on-demand platform. The study found that each approach has its merits, but that gradually releasing shows boosts consumers’ ...
Sleep strengthens muscle and bone by boosting growth hormone levels. Here's how
2025-09-08
As every bodybuilder knows, a deep, restful sleep boosts levels of growth hormone to build strong muscle and bone and burn fat. And as every teenager should know, they won't reach their full height potential without adequate growth hormone from a full night's sleep.
But why lack of sleep — in particular the early, deep phase called non-REM sleep — lowers levels of growth hormone has been a mystery.
In a study published in the current issue of the journal Cell, researchers from University ...
Only 1 in 7 online health images show proper technique to accurately measure blood pressure
2025-09-08
Research Highlights:
Only 1 in 7 online stock images of blood pressure monitoring aligned with the procedures recommended by clinical guidelines.
Online stock images depicting blood pressure monitoring in the home were approximately three times more accurate than images depicting blood pressure monitoring in a physician’s office, health care facility or hospital.
This study is among the first to review online images of people having their blood pressure measured from major stock photo websites.
Embargoed until 2 p.m. CT/3 p.m. ET Monday, ...
Children receiving biofeedback speech therapy improved faster than with traditional methods
2025-09-08
Run. Red. World. Pronouncing the “r” sound in these words requires precise control of the tongue. For most children, this happens naturally, but many children struggle with residual speech sound disorder (RSSD) in which speech errors persist past the age of eight.
In a large-scale study, researchers in speech pathology tested a promising treatment approach that incorporates biofeedback—a method that uses technology to provide visual feedback to improve speech. They found that children’s ability to say the “r” sound improved at a ...
Scientists discover why the flu is more deadly for older people
2025-09-08
Scientists have discovered why older people are more likely to suffer severely from the flu, and can now use their findings to address this risk.
In a new study, which is published in PNAS, experts discovered that older people produce a glycosylated protein called apoplipoprotein D (ApoD), which is involved in lipid metabolism and inflammation, at much higher levels than in younger people. This has the effect of reducing the patient’s ability to resist virus infection, resulting in a more serious disease outcome.
The team established that highly elevated ApoD production ...
The salmon superfood you’ve never heard of
2025-09-08
In northern California, salmon are more than just fish—they’re a cornerstone of tribal traditions, a driver of tourism and a sign of healthy rivers. So it may not come as a surprise that NAU and University of California Berkeley scientists working along the region’s Eel River have discovered a micro-scale nutrient factory that keeps rivers healthy and allows salmon to thrive.
The scientists’ new study in Proceedings of the National Academy of Sciences (PNAS) reveals how a partnership ...
How does chemotherapy disrupt circadian rhythms?
2025-09-08
During and after chemotherapy, nearly half of cancer patients endure circadian rhythm disruptions, which worsens treatment side effects. Because the body’s primary rhythm pacemaker is in the brain, this suggests that perhaps chemotherapeutics target the brain to disrupt circadian rhythms. However, research shows that cancer treatments do not penetrate the brain well. To shed light on this discrepancy, researchers led by Leah Pyter at Ohio State University explored whether paclitaxel, a frequently used breast cancer treatment, disrupts the biological clock in the brain to impair circadian rhythms.
In their eNeuro paper, the researchers used a paclitaxel treatment regimen ...